Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07623239

Predicting BPH Surgery Outcomes Using a Preoperative Scoring System

This study aims to develop and validate a preoperative predictive scoring system for surgical outcomes in patients with benign prostatic hyperplasia (BPH) undergoing prostate surgery (including but not limited to transurethral resection of the prostate, laser enucleation, photoselective vaporization, or robot-assisted simple prostatectomy).

It is a multicenter retrospective study involving patients from four hospitals in China. Preoperative multidimensional objective indicators, including clinical data, prostate MRI parameters, and urodynamic measurements, will be collected. The primary outcome is a favorable surgical response defined by a postoperative-to-preoperative International Prostate Symptom Score (IPSS) ratio ≤ 0.5 at 6 months after surgery.

Multivariable logistic regression, restricted cubic splines, and bootstrap internal validation will be used to construct and evaluate the scoring system. The goal is to provide an objective, individualized tool for optimizing surgical decision-making in BPH patients.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • - Postoperative pathological diagnosis of benign prostatic hyperplasia (BPH)
  • Completion of pelvic or prostate magnetic resonance imaging (MRI) plain scan within 1 month before surgery
  • Completion of urodynamic study within 1 month before surgery
  • Completion of International Prostate Symptom Score (IPSS) both before and after surgery
  • Complete and retrievable clinical and pathological data
  • Generally good condition without infection, autoimmune disease, hematologic disease, or other malignancies
  • Complete follow-up data with follow-up duration of at least 6 months after surgery

Exclusion criteria

  • - Concomitant prostate cancer or other malignancies
  • Prior prostate surgery or pelvic radiotherapy
  • Severe cardiac, pulmonary, hepatic, or renal insufficiency precluding tolerance of surgery
  • Intraoperative or postoperative severe complications affecting efficacy assessment
  • Follow-up duration less than 6 months or missing key data
  • Poor patient compliance precluding completion of necessary assessments and follow-up
  • Incomplete clinical, imaging, urodynamic, or pathological data, or loss to follow-up

Treatment and study plan

Primary outcomes

  1. Proportion of patients with favorable surgical response at 6 months post-surgery

    Time frame: 6 months after surgery

    Favorable surgical response is defined as a ratio of postoperative International Prostate Symptom Score (IPSS) to preoperative IPSS ≤ 0.5 at 6 months after surgery. IPSS assesses lower urinary tract symptoms, with scores ranging from 0 to 35 (higher scores indicating more severe symptoms). A ratio ≤ 0.5 represents at least 50% improvement from baseline.

Study contacts

Contact information is provided by the study sponsor or research team.

Yong Wei

CONTACT

[email protected]

13960985927

Sponsors and collaborators

Lead sponsor

First Affiliated Hospital of Fujian Medical University

Other

Registry information

Official study title

Development and Clinical Application Value of a Predictive Scoring System for Postoperative Outcomes Following Transurethral Resection of the Prostate Based on Preoperative Multidimensional Objective Indicators

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jun 3, 2026
Registry last updated
Jun 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.